Coulter Post Doctoral Scholars

The Coulter Center Post-Doctoral Scholars grants support innovative translational research projects that are conceived of by postdocs.

The Post-Doctoral Scholar Research Grant supports up to $25,000 a project, for initiating and advancing innovative translational research projects that are conceived of by postdocs within the department of BME. While also providing an impactful translational research training experience for postdocs. This grant is intended to support trainee-led research that will enhance their postdoctoral training experience and make them competitive for the next steps in their career. It will also help them generate strong preliminary data to be used in publications, secure external funding, and/or help them prepare for their independent careers. 

In line with the philosophy of the Wallace H. Coulter Center for Translational Research of promoting “Science serving humanity”, applications for the Post-Doctorial Scholar Research Grant must lay out a direct path for how the proposed work has the potential to improve patient wellness.

Selected Coulter Scholars will recevie $20-25k per project for 1 year, with a one-time no-cost extension of 6 months.

1. The applicant should be a postdoctoral trainee, at any stage, who is working with a PI who has a primary, joint, or courtesy appointment in the Department of Biomedical Engineering (BME).

2. The proposal will be reviewed for merit and suitability within the missions of the Center.

3. The applicant needs to identify a clinical co-mentor for the proposal who will provide mentorship
and guidance toward identifying the clinical implications of the research project. NOTE: the applicant’s PI and co-mentor must be different people.

4. Awarded Scholars are required to submit a one page progress report 6 months into funding cycle.

5. Coulter Scholars are required to participate in a one hour Translational Grant Writing Workshop that is led by BME faculty. 

  1. Curriculum vitae
  2. Research plan: No more than 2 pages of single-spaced text. Font size should Arial 11 points, and margins should be greater than or equal to 0.5 inches. References are not included in the 2-page limit.
  3. Professional development plan (limited to 300 words)
    1. This should outline the training plan during the period of the award. Include a description of the minimum of 10 hours of workshops/seminars that will be attended and why they were chosen to enhance the applicant’s knowledge of scientific communication, project management, and intellectual property. 
  4. Health impact statement (limited to 500 words)
    1. This should outline epidemiological information, the current clinical practice, and how the proposed research can lead to an outcome that will benefit patients.
  5. Proposed budget
  6. Letter of mentorship from translational co-mentor
    1. This letter describes how the co-mentor will support the applicant, the nature of the translational guidance, and how frequently the co-mentor will meet with the applicant.
    2.  Curriculum vitae of co-mentor
  7. Signed agreement of support from PI and co-signed by clinical co-mentor (template)
    1. This letter indicates that the proposed project differs from already funded research within the lab and that the PI endorses the application.  

Awardees will participate in at least 10 hours of training to enhance their knowledge of scientific communication, project management, and intellectual property. Possible training activities include the Innovation, Commercialization, or Communicating Research Series offered by the PhD+ Program, grant and research development through iTHRIV at UVA, or educational events offered through the UVA Licensing & Ventures Group.

Awardees will also attend a translational grant writing workshop that will be held within UVA BME during the Spring 2024 semester. 

Decisions shall be made by a program committee that is comprised of Brian Helmke, Associate Professor of BME, Mohammad Fallahi-Sochani, Associate Professor of BME, and Patrick Cottler, Director of Resident Research UVA.

Once selection decisions have been finalized, the awardee will receive a confirmation letter.

Each project will receive a unique funding worktag. 

Applications for the 2023 funding cycle are due by July 14th, 2023.

Please contact UVACOULTER@VIRGINIA.EDU if you are interested in applying. 

How will I receive the Scholar funding? 

Awardees will receive unique funding worktag to use during the active funding cycle.

Can I apply for funding more than once? 

Postdocs are eligible to apply for the Scholars grant multiple times throughout training at UVA. 

What can I use the funding for? 

The funds are intended to support the advancement of translational research projects conceived by BME postdoctoral trainees. A detailed budget justification is requiremed in the proposal.

2024-2025 Coulter Scholar Projects

Predicting radioresistance risk using primary luminal breast cancer organoids and gene expression signatures

Project PI: Dr. Róża K. Przanowska

Luminal breast cancer is a subtype characterized by estrogen receptor positivity (ER+), low levels of human epidermal growth factor receptor 2 (HER2), and low proliferation indices such as Ki-67. It has the best prognosis among breast cancer subtypes with 95.1% five-year relative survival. Standard treatments include surgery, hormone therapy, chemotherapy, and radiation therapy. However, the cancer's ability to withstand radiation therapy — radioresistance — poses significant challenges for effective treatment and patient outcomes. Reduced efficacy of residual disease elimination means higher chances of local recurrence and metastasis. While luminal breast cancer generally has a favorable prognosis, radioresistance leads to decreased survival rates and necessitates alternative or adjunctive treatments.

Systems identification of dietary supplements to prevent congenital heart defects

Project PI: Dr. Alexander Clark

Congenital heart defects (CHDs) are the most prevalent severe congenital disorder and a

leading cause of infant morbidity in the Western world, affecting 1-2% of all live births. These

defects typically arise before birth, causing abnormalities in heart structure and function. While

CHDs vary in severity, they all contribute to morbidity and, in many cases, are fatal. Additionally,

treatment of CHDs, which often require several surgeries, are a substantial strain on the

healthcare system and upend the lives of families who are affected. On average, the cost per

individual with complex CHDs is $650k in the first five years, with an average of $195k paid

directly by families. Despite the clear need for preventative CHD treatments, the incidence of

CHDs has remained stubbornly constant for the last three decades. This is because there are

no therapies that effectively reduce the occurrence of CHDs.

Identification of the regulatory effect of sodium-glucose cotransporter 2 inhibitors on inflammatory pathways in ANOCA patients

Project PI: Dr. Kelsey Watts

Heart disease is the leading cause of death for both men and women. However, there has been a historical underrepresentation of female participants in clinical trials and research, resulting in lower drug effectiveness and twice the risk of adverse reactions in female patients. This disparity is further complicated by the influence of biological sex on disease development and presentation. For instance, while coronary artery disease (CAD) is commonly associated with arterial blockage by fatty plaques in males, females are equally prone to non-obstructive CAD. Patients with angina and non-obstructive coronary artery disease (ANOCA) often exhibit microvascular inflammation, leading to vasospasm and reduced blood flow. Unfortunately, diagnosing ANOCA is more challenging than obstructive CAD, and there are limited guidelines for prevention and targeted treatments that consider the diverse underlying mechanisms. Current treatment regimens, which often involve statins, aspirin, beta-blockers, or other non-specific cardiovascular drugs, do not adequately address the specific needs of ANOCA patients, particularly females, and can lead to increased adverse effects and reduced efficacy.